1. Company Profile
• Symbol: $TEM
• Market Value: $13.99 billion
• Business Sector: Healthcare technologies – AI-enabled diagnostics, genomic analysis, and data services
• Stock Exchange: NASDAQ
• Indices: Not included in any index.
• Headquarters & Year Founded: Chicago, Illinois, USA – 2015
• Founder-led Company: Yes – Founder and CEO: Eric Lefkofsky
• What Does It Do?: Provides personalized medicine solutions. AI-enabled diagnostic and data systems analyze genome sequencing, clinical/molecular/imaging data, providing solutions to healthcare, pharmaceutical companies, and researchers.
• Multinational?: While it has global partnerships, it is currently only US-based.
• Number of Employees: 2,400
• Institutional Ownership: Not fully disclosed, but major investors include SoftBank, Baillie Gifford, and Google. Additionally, 40.42% of the shares are held by insiders (specifically Eric Lefkofsky: 25.6%).
• Insider Activity: Eric Lefkofsky owns 44.5 million shares, with a market capitalization of $3.3B.
2. Revenue Streams (How Does It Make Money?)
• Genomics Segment: $193.8M in Q1 2025 (76% of total revenue) – 89% Y/Y growth
• Data & Services Segment: $61.9M – 43% Y/Y growth
Main Products and Services:
• Oncology & hereditary genetic testing
• Data analysis services (AI-assisted diagnostics, MRD, Deep 6, etc.)
• $200M 3-year modeling agreement with AstraZeneca and Pathos
3. Financial Health
• Gross Margin: Strong for non-manufacturing services at 60.7%. 50%+ is considered very good.
• Net Profit Margin: -21.0% Not yet profitable. Negative.
• Sales Growth (5Y): 62.0%
Comment: High growth above 20%; this is very positive.
• EPS Growth (3Y): 9.6% (Comment: Weak; 20%+ would signal healthier growth.)
• Long-term Debt / Equity: 2.8 (Comment: High; a debt burden above 1 is risky.)
• Debt/Cash Ratio: $561.95M debt / $291.3M cash → debt/cash ratio ≈ 1.93 (Comment: Even if there is no red flag, debt should be checked.)
• P/E and Forward P/E: P/E cannot be calculated because of negative earnings; this increases valuation risk.
• Price to Free Cash Flow (P/FCF): 127.2 (Note: Very high; below 20 is good.)
• Free Cash Flow (FCF): -7.3% (Note: Negative free cash flow is a negative signal)
4. Note to Investors
Strengths:
• Rapidly growing revenue: $531M in 2023 → $693M in 2024 → 2025 projection: $1.26B
• 40–90% growth in genomic and data segments
• Major partnerships with AstraZeneca and a $1B+ contract portfolio
• Targeting positive EBITDA in 2025
• Potential new growth areas such as an AI-driven business model and MRD
Weaknesses:
• Net losses continue: EBITDA margin -17%, net profit margin -21%
• Valuation expensive (P/FCF 127x)
• Debt/Equity ratio of 2.8 – increasing financial risks
• Earnings estimates remain negative and profitability is uncertain
• Majority of revenues are dependent on a limited number of strategic partnerships (AstraZeneca, Pathos)
5. Analyst Average Target Prices
• Target Price (Average): $71
• Direction: -11.8% downside potential
• BTIG has set a target of $85, while TD Cowen has set a target of $72.
6. Summary
Tempus AI is a rapidly growing company in the field of genomic data and AI-enabled healthcare technologies. Annual revenue growth of nearly 50% is projected through 2025. High revenue growth from genomic testing and data analytics services is encouraging for investors. However, the company remains unprofitable and has high debt. While its founding leadership, major partnerships with Google and Softbank, and aggressive growth targets are strengths, Factors such as failure to achieve profitability, valuation risk, and financial leverage are significant weaknesses.
Therefore, it is worth monitoring for "investors seeking high growth but with a high risk tolerance." However, it is not a suitable company for investors with a value investing approach or those seeking safer companies.
I read Tempus AI's latest earnings call and was quite impressed. Tempus's latest earnings statement clearly demonstrated why the company has begun to be viewed as a "special player" at the intersection of healthcare and AI. Management emphasized that they prioritize long-term, sustainable growth over short-term explosive growth.
Targeting steady annual growth of 25% was presented as a much healthier strategy than growing 50% one year and then dropping to 10% the next. The company's most striking strength is its unique data assets. Today, Tempus AI holds over 350 petabytes of clinical and genomic data. This vast data is constantly fed through connections with more than 4,500 healthcare institutions. Integration with these institutions not only collects data but also provides meaningful AI-processed insights to doctors, patients, and researchers.
Management emphasizes this point: it's nearly impossible to imagine a healthcare company that would choose to proceed "the old way" when it possesses such a large and valuable dataset. The infrastructure Tempus has built to process this data is also remarkable. The company uses months of processing power on a cluster of over 1,000 NVIDIA H200 GPUs.
Many companies in the healthcare sector talk about advanced chips like the H200, but few actually use them at this scale. This position positions Tempus not only as a contender in AI applications but also as a true implementer. On the competitive front, management demonstrates a highly confident stance. They stated that they don't see any direct competitors challenging them in the data and AI space.
Their lost deals are generally not because customers aren't yet ready to purchase such a product or because they've turned to other competitors. This is because there aren't yet any competitors doing what Tempus does. This further strengthens Tempus's position.
Furthermore, the company's pipeline is remarkably robust. Even as major pharmaceutical companies cut their R&D budgets, there's no reduction in resources allocated to data and AI. This is a very positive sign for Tempus's business model. New products planned for rare diseases and pediatrics, in particular, have been cited as potential catalysts.
In conclusion, Tempus proves that it not only collects big data; it also possesses the scale, technology, and vision to process it and transform it into meaningful solutions for the healthcare sector. This position truly positions the company in a unique position at the intersection of healthcare and AI. What do you think? Could Tempus AI become the Palantir of healthcare?
The information, comments and recommendations contained herein are not within the scope of investment consultancy. Investment consultancy services are provided within the framework of the investment consultancy agreement to be signed between brokerage firms, portfolio management companies, banks that do not accept deposits and customers. The comments in this article are only my personal comments and these comments may not be appropriate for your financial situation and risk return. For this reason, investments should not be made based on the information and comments in my articles.
